Showing results (161-170 of 782) with videos related to

Sort By:
Pageof 79
The Lancet. HIV|February 2, 2026
Cigarette smoking in PrEP recipients: a challenge and an opportunityJonathan Shuter, Nancy A Rigotti, Krishna P Reddy, et al.
The Lancet. HIV|January 17, 2026
Safety, antiviral activity, and pharmacokinetics of long-acting injectable cabotegravir-rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multinational, phase 1/2, single-arm studyAditya H Gaur, Kristin Baltrusaitis, Edmund V Capparelli, et al.
The Lancet. HIV|January 18, 2026
Assessing the effectiveness of a depression-integrated model in adult HIV care in Uganda (the HIV+D trial): a cluster-randomised controlled trialEugene Kinyanda, Leticia Kyohangirwe, Richard S Mpango, et al.
The Lancet. HIV|December 5, 2025
Strengthening nationally led approaches to new product introduction for HIV preventionHasina Subedar, Nondumiso B Q Ncube, Herbert Kadama, et al.
The Lancet. HIV|December 4, 2025
Fixed-dose combination bictegravir-emtricitabine-tenofovir alafenamide twice-daily for treatment of HIV during rifampicin-based tuberculosis treatment (INSIGHT Study): a phase 2b, open-label, randomised non-comparative trialAnushka Naidoo, Kogieleum Naidoo, Marothi P Letsoalo, et al.
The Lancet. HIV|January 9, 2025
Event-driven PrEP beyond cisgender men who have sex with menWhitney C Irie, Melanie R Nicol, Meredith Clement, et al.
The Lancet. HIV|December 16, 2024
Adaptive HIV pre-exposure prophylaxis adherence interventions for young women in Johannesburg, South Africa: a sequential multiple-assignment randomised trialJennifer Velloza, Nicole Poovan, Allison Meisner, et al.
The Lancet. HIV|February 6, 2025
Costs and outcomes of routine HIV oral pre-exposure prophylaxis implementation across different service delivery models and key populations in South Africa: a retrospective cohort studyCheryl Hendrickson, Kamban Hirasen, Constance Mongwenyana, et al.
The Lancet. HIV|December 13, 2024
Lesotho's progress towards UNAIDS 95-95-95 targets from 2016 to 2020: comparison of Population-based HIV Impact AssessmentsMansoor Farahani, Shannon M Farley, Theodore F Smart, et al.
The Lancet. HIV|January 6, 2025
Target product profile for cell-based and gene-based therapies to achieve a cure for HIVSharon R Lewin, Cathy Bansbach, Dominic Kemps, et al.
Pageof 79